FDA Warns Against Concurrent Use Of Triptans With SSRIs/SNRIs
This article was originally published in The Pink Sheet Daily
The agency has received reports of serotonin syndrome caused by use of the migraine therapy class with antidepressants, according to a public health advisory.
You may also be interested in...
Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.